Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6698826 | 0.90 | F10 (0.48) | F10BDKRB1 | |
| SCHEMBL6695833 | 0.86 | F10 (0.64) | F10ALDH1A1HTT | |
| SCHEMBL6698165 | 0.85 | F10 (0.63) | F10ALDH1A1HTT | |
| SCHEMBL6695837 | 0.84 | F10 (0.47) | F10ALDH1A1HTTCYP3A4CYP2C19 | |
| SCHEMBL7004429 | 0.83 | F10 (0.44) | F10ALDH1A1HTTCYP3A4CYP2C19 | |
| SCHEMBL6694660 | 0.82 | F10 (0.64) | F10 | |
| SCHEMBL6693699 | 0.78 | F10 (0.70) | F10 | |
| SCHEMBL6695522 | 0.76 | F10 (0.69) | F10 | |
| SCHEMBL6695519 | 0.74 | F10 (0.49) | F10 | |
| SCHEMBL6695516 | 0.74 | F10 (0.49) | F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072860-A1 | Piperazin-2-one amides as inhibitors of factor xa | F2, TFPI, TFPI2 | F10 12/4885ALDH1A1 1970/4885HTT 4230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.